Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (11717)	10/2/2018 2:56:55 PM
From: Miljenko Zuanic	Respond to of 12215

RE: VKTX So, it may bail out to 2809. I do believe (and all data so far demonstrate that) THRbeta path is "the best" target, so far, IF one have to control triglycerides and other lipids, by one word "unwanted" excess fat! Long term safety need to be demonstrated clearly, broad "metabolic" use (not NASH only). It may take time for this ( for 2809 and 3916)... I mentioned early, secondary after nash day I would see as weakens...and it is just confirmed.

To: Miljenko Zuanic who wrote (11717)	10/2/2018 3:45:54 PM
From: tuck	Read Replies (2) \| Respond to of 12215

So, guys, I largely agree with your takes. I was posting a bear case that I think is overstated. It's not a fail, as he says, it's just too early. Nevertheless, the market seems to be reacting as he did. Did the market really expect sustained anabolic response after end of treatment? Even I didn't, before Rick responded. So, like Rick, I've been buying into that weakness, having sold a second tranche of puts this morning. Though I'll agree with the bearish guy that we could have been given more data than we were (i.e. baseline characteristics, gender, actual lipid and triglyceride data, etc.), and that may suggest to Mr. Market the company is hiding bad news, hence the renewed pummeling. However, as far as I know, for approval, 5211 would need an actual fracture endpoint. We have no human data wrt to bone effects, right? No BMD measurements? So all we currently have is preclinical data, namely this: VK5211 Preclinical Data Is that plus the human data so far enough for a partner? Or would a prospective partner also like to see human bone data? In which case, Viking had better design the next trial accordingly, and it would be nice if they start talking to investors about the anticipated trial design, and soon. Cheers, Tuck